Published in Hepatitis Weekly, January 1st, 2007
The primary endpoint is comparative seroprotection after the second dose. The data was reported in a poster at the Canadian Immunization Conference in Winnipeg, Manitoba, Canada by Dr. Scott A. Halperin, professor of pediatrics and microbiology and immunology at Dalhousie University and head of pediatric infectious disease at the Halifax-based IWK Health Center.
The data show that 100% seroprotection is achieved whether the second dose is administered one or two months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.